NL8700366A - Combinatie van fu met bvdu als middel tegen adenocarcinoom. - Google Patents

Combinatie van fu met bvdu als middel tegen adenocarcinoom. Download PDF

Info

Publication number: NL8700366A
Authority: NL; Netherlands
Prior art keywords: fluorouracil; bvdu; bromovinyl; combination; deoxyuridine
Prior art date: 1987-02-13

Application number

NL8700366A

Other languages

English (en)

Dutch (nl)

Original Assignee

Stichting Rega V Z W

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-02-13

Filing date

1987-02-13

Publication date

1988-09-01

1987-02-13 Application filed by Stichting Rega V Z W filed Critical Stichting Rega V Z W

1987-02-13 Priority to NL8700366A priority Critical patent/NL8700366A/nl

1988-02-10 Priority to JP63031681A priority patent/JP2688057B2/ja

1988-02-11 Priority to US07/154,193 priority patent/US4894365A/en

1988-02-12 Priority to AT88200265T priority patent/ATE63817T1/de

1988-02-12 Priority to DE8888200265T priority patent/DE3862961D1/de

1988-02-12 Priority to ES88200265T priority patent/ES2032942T3/es

1988-02-12 Priority to EP88200265A priority patent/EP0283065B1/de

1988-09-01 Publication of NL8700366A publication Critical patent/NL8700366A/nl

1989-06-29 Priority to US07/373,824 priority patent/US4988678A/en

1991-08-02 Priority to GR91401120T priority patent/GR3002431T3/el

Links

208000009956 adenocarcinoma Diseases 0.000 title claims abstract description 15
ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 title claims description 29
229960002949 fluorouracil Drugs 0.000 claims abstract description 12
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 10
BLXGZIDBSXVMLU-OWOJBTEDSA-N 5-[(e)-2-bromoethenyl]-1h-pyrimidine-2,4-dione Chemical compound Br\C=C\C1=CNC(=O)NC1=O BLXGZIDBSXVMLU-OWOJBTEDSA-N 0.000 claims abstract 3
238000002360 preparation method Methods 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 5
239000003814 drug Substances 0.000 claims 6
239000013543 active substance Substances 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
229940126601 medicinal product Drugs 0.000 claims 1
238000000034 method Methods 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 7
231100000419 toxicity Toxicity 0.000 abstract description 7
230000001988 toxicity Effects 0.000 abstract description 7
230000000259 anti-tumor effect Effects 0.000 abstract description 4
239000000203 mixture Substances 0.000 abstract description 4
239000002243 precursor Substances 0.000 abstract description 3
206010028980 Neoplasm Diseases 0.000 description 7
230000000694 effects Effects 0.000 description 5
230000037396 body weight Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
241000699670 Mus sp. Species 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
231100001274 therapeutic index Toxicity 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
231100000111 LD50 Toxicity 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
229960001674 tegafur Drugs 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

NL8700366A 1987-02-13 1987-02-13 Combinatie van fu met bvdu als middel tegen adenocarcinoom. NL8700366A (nl)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
NL8700366A NL8700366A (nl)	1987-02-13	1987-02-13	Combinatie van fu met bvdu als middel tegen adenocarcinoom.
JP63031681A JP2688057B2 (ja)	1987-02-13	1988-02-10	抗腺がん剤
US07/154,193 US4894365A (en)	1987-02-13	1988-02-11	Combinations of FU and BVU as anti-adenocarcinoma agents
AT88200265T ATE63817T1 (de)	1987-02-13	1988-02-12	Mischungen von fu und bvu als adenokarzinomhemmende mittel.
DE8888200265T DE3862961D1 (de)	1987-02-13	1988-02-12	Mischungen von fu und bvu als adenokarzinomhemmende mittel.
ES88200265T ES2032942T3 (es)	1987-02-13	1988-02-12	Un procedimiento para preparar un medicamento para uso contra adenocarcinomas.
EP88200265A EP0283065B1 (de)	1987-02-13	1988-02-12	Mischungen von FU und BVU als adenokarzinomhemmende Mittel
US07/373,824 US4988678A (en)	1987-02-13	1989-06-29	Combinations of FU and BVU as anti-adenocarcinoma agents
GR91401120T GR3002431T3 (en)	1987-02-13	1991-08-02	Combinations of fu and bvu as anti-adenocarcinoma agents

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL8700366A NL8700366A (nl)	1987-02-13	1987-02-13	Combinatie van fu met bvdu als middel tegen adenocarcinoom.
NL8700366		1987-02-13

Publications (1)

Publication Number	Publication Date
NL8700366A true NL8700366A (nl)	1988-09-01

Family

ID=19849574

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8700366A NL8700366A (nl)	1987-02-13	1987-02-13	Combinatie van fu met bvdu als middel tegen adenocarcinoom.

Country Status (8)

Country	Link
US (2)	US4894365A (de)
EP (1)	EP0283065B1 (de)
JP (1)	JP2688057B2 (de)
AT (1)	ATE63817T1 (de)
DE (1)	DE3862961D1 (de)
ES (1)	ES2032942T3 (de)
GR (1)	GR3002431T3 (de)
NL (1)	NL8700366A (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5137724A (en) *	1990-05-23	1992-08-11	Stichting Rega Vzw	Combinations of TS-inhibitors and viral TK-inhibitors in antiherpetic medicines
WO1996023506A1 (de) *	1995-02-01	1996-08-08	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside
ATE413881T1 (de)	1997-08-08	2008-11-15	Celmed Oncology Usa Inc	Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
ES2172303T3 (es)	1998-01-23	2002-09-16	Newbiotics Inc	Agentes terapeuticos obtenidos por catalisis enzimatica.
US7462605B2 (en)	1998-01-23	2008-12-09	Celmed Oncology (Usa), Inc.	Phosphoramidate compounds and methods of use
IL147749A0 (en)	1999-07-22	2002-08-14	Newbiotics Inc	Methods for treating therapy-resistant tumors
EP1251836A2 (de) *	1999-12-23	2002-10-30	NewBiotics, Inc.	Verwendung von bvdu zur hemmung von hyperproliferativem zellwachstum
DE10108851A1 (de) *	2001-02-23	2002-09-12	Resprotect Gmbh	Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2016921B (en) *	1978-03-27	1982-08-18	Taiho Pharmaceutical Co Ltd	Anti cancer compositions containing uracil derivatives
IT1170232B (it) *	1983-10-31	1987-06-03	Anna Gioia Stendardi	Composizioni terapeutiche ad attivita' antivirale
DE3667915D1 (de) *	1985-01-30	1990-02-08	Hoffmann La Roche	Pharmazeutische zusammensetzung.

1987
- 1987-02-13 NL NL8700366A patent/NL8700366A/nl not_active Application Discontinuation
1988
- 1988-02-10 JP JP63031681A patent/JP2688057B2/ja not_active Expired - Lifetime
- 1988-02-11 US US07/154,193 patent/US4894365A/en not_active Expired - Fee Related
- 1988-02-12 ES ES88200265T patent/ES2032942T3/es not_active Expired - Lifetime
- 1988-02-12 AT AT88200265T patent/ATE63817T1/de not_active IP Right Cessation
- 1988-02-12 EP EP88200265A patent/EP0283065B1/de not_active Expired - Lifetime
- 1988-02-12 DE DE8888200265T patent/DE3862961D1/de not_active Expired - Fee Related
1989
- 1989-06-29 US US07/373,824 patent/US4988678A/en not_active Expired - Fee Related
1991
- 1991-08-02 GR GR91401120T patent/GR3002431T3/el unknown

Also Published As

Publication number	Publication date
ATE63817T1 (de)	1991-06-15
GR3002431T3 (en)	1992-12-30
EP0283065A1 (de)	1988-09-21
US4988678A (en)	1991-01-29
JPS63203619A (ja)	1988-08-23
JP2688057B2 (ja)	1997-12-08
US4894365A (en)	1990-01-16
ES2032942T3 (es)	1996-07-16
EP0283065B1 (de)	1991-05-29
DE3862961D1 (de)	1991-07-04

Legal Events

Date	Code	Title	Description
1988-09-01	A1B	A search report has been drawn up
1992-10-01	BV	The patent application has lapsed

Publication	Publication Date	Title
DE60105424T2 (de)	2005-09-22	Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
JPH10511689A (ja)	1998-11-10	アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法
JP2584947B2 (ja)	1997-02-26	アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤毒性の治療
WO1999051246A1 (en)	1999-10-14	Antitumor agents
EP0281380B1 (de)	1995-11-29	Synergistische Wechselwirkung von Interleukin-2 und doppelsträngiger RNS
NL8301913A (nl)	1983-12-16	Middel voor het versterken van de antitumor activiteit van een middel tegen tumoren.
EP0283065B1 (de)	1991-05-29	Mischungen von FU und BVU als adenokarzinomhemmende Mittel
Kimura et al.	1980	Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2′-tetrahydrofuryl)-5-fluorouracil
Eriguchi et al.	1997	Pilot study for preoperative administration of 1-OHP to patients with advanced scirrhous type gastric cancer
JP2002515892A (ja)	2002-05-28	サイトカインが関係する疾患治療法
Masaaki et al.	1989	Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5′-deoxy-5-fluorouridine against adenocarcinoma 755 in mice: Correlation with pharmacokinetics of plasma 5-fluorouracil levels
Vadlamudi et al.	1970	Effect of combination treatment with 5-azacytidine and cytidine on the life-span and spleen and bone marrow cells of leukemic (L1210) and nonleukemic mice
LV10574B (en)	1995-08-20	The therapeutic use of low concentrations of trinitrobenzene, carminic acid and their derivatives as anti-cancer and anti-viral agents
JPH0529365B2 (de)	1993-04-30
US7671038B1 (en)	2010-03-02	Method of therapeautic treatments including human immunodeficiency virus (HIV) disease and other conditions in a human host by administering adenine nucleotides
CN108601792B (zh)	2021-10-29	治疗细菌感染的新方法
Saijo et al.	1992	Changes in serum erythropoietin levels during chemotherapy for lung cancer
DE3007777C2 (de)	1989-09-07
JPS6231690B2 (de)	1987-07-09
JPH0145450B2 (de)	1989-10-03
JPS6337767B2 (de)	1988-07-27
JPH09188623A (ja)	1997-07-22	レトロウイルス感染治療剤
JPH0332528B2 (de)	1991-05-13
JPS6345372B2 (de)	1988-09-09
JPS6223724B2 (de)	1987-05-25